HSCS

HeartSciences Inc. (HSCS) Economic Moat Analysis (2026)

Invetso Score: 1/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 1.0 (Weak)

HSCS has no provided evidence of proprietary brands, patents, or regulatory licenses that would let it charge peers a premium or protect margins over 5–10 years.

The negative TTM ROIC and ROCE indicate that any intangible advantage is not translating into durable economic returns versus peers.

With no disclosed long-run margin history or identifiable IP moat in the supplied data, its positioning appears more replicable than differentiated relative to competitors.

Switching Costs

Score:

The extremely weak TTM efficiency profile and negative returns suggest customers are not locked in by high switching costs that preserve pricing power versus peers.

No filing-based evidence was provided of contractual lock-in, embedded workflows, or integration depth that would make replacement costly for customers.

Compared with stronger software or platform peers, HSCS shows no visible retention moat in the supplied metrics, so switching costs appear minimal.

Network Effects

Score:

The provided data contains no indication of user, data, or ecosystem effects that would make the product more valuable as adoption rises.

Negative profitability and near-zero asset turnover are inconsistent with a platform that benefits from self-reinforcing scale versus peers.

Absent evidence of a two-sided market or industry-standard network, HSCS does not appear to have a durable network-effect moat.

Cost Advantage

Score:

HSCS does not show a cost advantage in the supplied metrics because negative ROIC and ROCE imply it is not converting capital into returns better than peers.

The very low asset turnover suggests weak operating efficiency rather than a structurally lower-cost model.

Without evidence of scale purchasing, process superiority, or lower unit costs in filings, its cost position appears inferior to stronger competitors.

Efficient Scale

Score:

The data does not show evidence that HSCS operates in a niche where limited market size protects returns from competition better than peers.

Negative returns and extreme working-capital inefficiency argue against a profitable scale position that deters entry or supports stable margins.

Compared with firms that benefit from concentrated markets or regulated capacity, HSCS shows no sign of efficient-scale protection in the supplied metrics.

Overall Score

Score:

HSCS appears to have a very weak and non-durable moat versus peers based on the supplied metrics, with no visible evidence of intangible assets, switching costs, network effects, cost advantage, or efficient scale translating into sustained pricing power or retention.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on HeartSciences Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →